We found that MIA3 expression was significantly altered in lung adenocarcinoma (LUAD), breast invasive carcinoma (BRCA), oesophageal cancer (ESCA), gastric and oesophageal cancer (STES), mixed kidney cancer (KIPAN), gastric cancer (STAD), prostate cancer (PRAD), head and neck squamous cell carcinoma (HNSC), clear cell carcinoma of the kidney (KIRC), lung squamous cell carcinoma (LUSC), and hepatocellular carcinoma (LIHC) samples versus control samples. Here, MIA3 is linked to prostate adenocarcinoma.